Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05915208 · ClinicalTrials.gov registry record
Histiocytic Disorder Follow-up Study
A clinical trial of Langerhans Cell Histiocytosis and Histiocytosis, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 6,000
- Enrollment target
- 1
- Study location
NCT05915208: Recruiting study of Langerhans Cell Histiocytosis and Histiocytosis, sponsored by University of Alabama at Birmingham.
NCT05915208 is a study of Langerhans Cell Histiocytosis and Histiocytosis that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 6,000 participants, above the 389-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (1442% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05915208, a study of Langerhans Cell Histiocytosis and Histiocytosis, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 6,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders
Primary Outcome
The CTCAE criteria for CHCs distinguishes each acute and chronic condition (including SPMs) in persons with cancer from grades 1 through 4 with unique clinical descriptions of severity (grade 1, mild; grade 2, moderate; grade 3, severe; grade 4, life-threatening/disabling). The main outcome will be the number of distinct CTCAE grade 3-4 conditions among LCH cases compared with unaffected (non-cancer) controls.
Conditions Studied
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2028-12 |
What NCT05915208 shows while recruiting
NCT05915208 is an observational study that tracks outcomes without assigning an intervention. Its 6,000 participants enrollment target places it among the larger protocols in the corpus, above the 389-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (1442% higher).
The record links to 6 conditions, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 0 interventions.
NCT05915208 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT05915208 about?
NCT05915208 is a clinical study titled "Histiocytic Disorder Follow-up Study". The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders
What is the current status of trial NCT05915208?
This trial is currently recruiting. The enrollment target is 6,000 participants. The study started on 2022-09-01. Estimated completion is 2028-12.
What conditions does trial NCT05915208 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis, Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, Xanthogranuloma.
Who is sponsoring clinical trial NCT05915208?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05915208 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05915208's enrollment target sits among peer trials
6,000 1st of 8 higher than 8 of 8 other Langerhans Cell Histiocytosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Langerhans Cell Histiocytosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
RECRUITING · Phase 2
-
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
RECRUITING · Phase 2
-
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
RECRUITING · Phase 3
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
- NCT03127631 · 6,000 participants · NA
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
- NCT03539705 · 6,000 participants
Food Allergy Registry at a Single Site
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI